TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
Technology Revising Ultrasound Solutions for Tomorrow - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
Norwegian University of Science and Technology
250 participants
Mar 8, 2024
INTERVENTIONAL
Conditions
Summary
TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD). Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.
Eligibility
Inclusion Criteria1
- Breast cancer and referral for follow-up to identify potential CTRCD
Exclusion Criteria1
- Not willing or able to consent
Interventions
Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients
Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06310330